EQ — Equillium Inc
NASDAQ · Healthcare · Biotechnology
$2.28
+$0.07 (+3.40%)
Equillium Inc (EQ) is a biotechnology company listed on NASDAQ. It is led by Stephen Connelly Ph.D., based in 2223 Avenida De La Playa, La Jolla, CA, United States, 92037, with about 14 employees. Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Net income was -$18.6M. EQ currently screens at market cap $189.0M.
Use this EQ page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EQ quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EQ SEC filings page. Lician reads the product cache first so this HTML stays unique to Equillium Inc even when a live quote feed is slow.
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
EQ Key Statistics
Market Cap
$189.05M
Volume
394,414
Previous Close
$2.20
Day Range
$2.16 – $2.24
P/B Ratio
3.18
EPS
-$0.23
Revenue
$41.09M
Net Income
-$8.07M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+13.9%
Profit Margin
-19.6%
Employees
14
EQ Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $41.09M | $36.08M | $15.76M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.07M | -$13.34M | -$62.43M | -$39.05M |
| EPS (Diluted) | -$0.23 | -$0.38 | -$1.85 | -$1.36 |
Total Assets
$25.60M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$18.09M
Operating Cash Flow
-$19.03M
Free Cash Flow
$0.00
Equillium Inc Company Information
- Chief Scientific Officer & President
- Stephen Connelly Ph.D.
- Headquarters
- 2223 Avenida De La Playa, La Jolla, CA, United States, 92037
- Website
- www.equilliumbio.com
- Phone
- 858 240 1200
- IPO / Founded
- 2018-10-11
- Sector
- Healthcare
- Industry
- Biotechnology